Media headlines about Juno Therapeutics (NASDAQ:JUNO) have trended somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Juno Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.0147473909364 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Juno Therapeutics (NASDAQ:JUNO) traded down $0.35 during mid-day trading on Friday, reaching $85.10. 3,052,715 shares of the company’s stock traded hands, compared to its average volume of 6,330,000. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics has a 52 week low of $19.62 and a 52 week high of $86.28. The stock has a market cap of $9,720.00, a PE ratio of -25.10 and a beta of 3.42.
JUNO has been the subject of a number of research analyst reports. Cowen reaffirmed a “buy” rating and set a $49.00 price objective on shares of Juno Therapeutics in a research report on Friday, October 27th. Citigroup reaffirmed a “buy” rating and set a $59.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, October 31st. SunTrust Banks raised shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 2nd. Wedbush reaffirmed an “outperform” rating and set a $64.00 price objective (up previously from $42.00) on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Finally, Leerink Swann reaffirmed an “in-line” rating and set a $56.00 price objective (up previously from $34.00) on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, sixteen have given a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $51.20.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.